Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -32.51% | -96.07% | -93.80% | 117.25% | 186.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.51% | -96.07% | -93.80% | 117.25% | 186.01% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -32.51% | -96.07% | -93.80% | 117.25% | 186.01% |
| SG&A Expenses | 65.46% | 36.31% | 64.64% | 26.28% | 17.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.81% | 26.03% | 73.27% | 53.95% | 20.32% |
| Operating Income | -139.67% | -148.02% | -350.00% | -43.62% | 6.96% |
| Income Before Tax | -162.39% | -143.80% | -452.70% | -49.92% | 8.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -162.39% | -144.30% | -452.70% | -45.09% | 8.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -162.39% | -144.30% | -452.70% | -45.09% | 8.61% |
| EBIT | -139.67% | -148.02% | -350.00% | -43.62% | 6.96% |
| EBITDA | -141.94% | -147.42% | -364.95% | -44.75% | 6.74% |
| EPS Basic | -131.96% | -140.64% | -408.05% | -39.48% | 12.67% |
| Normalized Basic EPS | -131.93% | -140.19% | -407.92% | -44.10% | 12.67% |
| EPS Diluted | -131.96% | -141.73% | -407.02% | -39.21% | 12.67% |
| Normalized Diluted EPS | -131.93% | -141.26% | -407.92% | -44.10% | 12.67% |
| Average Basic Shares Outstanding | 13.13% | 8.99% | 8.79% | 4.03% | 4.64% |
| Average Diluted Shares Outstanding | 13.13% | 6.17% | 8.79% | 4.03% | 4.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |